

A CMS Medicare Administrative Contractor
<https://www.NGSMedicare.com>

Bibliography -KidneyIntelX

1. Tokita J, Vega A, Sinfield C, et al. Real World Evidence and Clinical Utility of KidneyIntelX on Patients With Early-Stage Diabetic Kidney Disease: Interim Results on Decision Impact and Outcomes. *J Prim Care Community Health*. Jan-Dec 2022;13:21501319221138196. doi:10.1177/21501319221138196
[10.1177_21501319221138196.pdf \(nih.gov\)](https://doi.org/10.1177_21501319221138196)
2. Nadkarni GN, Takale D, Neal B, et al. A Post Hoc Analysis of KidneyIntelX and Cardiorenal Outcomes in Diabetic Kidney Disease. *Kidney360*. Sep 29 2022;3(9):1599-1602. doi:10.34067/KID.0002172022
[A Post Hoc Analysis of KidneyIntelX and Cardiorenal Outcomes in Diabetic Kidney Disease - PMC \(nih.gov\)](https://doi.org/10.34067/KID.0002172022)
3. Lam D, Nadkarni GN, Mosoyan G, et al. Clinical Utility of KidneyIntelX in Early Stages of Diabetic Kidney Disease in the CANVAS Trial. *Am J Nephrol*. 2022;53(1):21-31. doi:10.1159/000519920
[Clinical Utility of KidneyIntelX in Early Stages of Diabetic Kidney Disease in the CANVAS Trial \(karger.com\)](https://doi.org/10.1159/000519920)
4. Chauhan K, Nadkarni GN, Fleming F, et al. Initial Validation of a Machine Learning-Derived Prognostic Test (KidneyIntelX) Integrating Biomarkers and Electronic Health Record Data To Predict Longitudinal Kidney Outcomes. *Kidney360*. Aug 27 2020;1(8):731-739. doi:10.34067/KID.0002252020
[KIDK3602020000225 731..739 \(nih.gov\)](https://doi.org/10.34067/KID.0002252020)
5. Liu C, Debnath N, Mosoyan G, et al. Systematic Review and Meta-Analysis of Plasma and Urine Biomarkers for CKD Outcomes. *J Am Soc Nephrol*. Sep 2022;33(9):1657-1672. doi:10.1681/ASN.2022010098
[Systematic Review and Meta-Analysis of Plasma and Urine Biomarkers for CKD Outcomes - PubMed \(nih.gov\)](https://doi.org/10.1681/ASN.2022010098)
6. Connolly P, Stapleton S, Mosoyan G, et al. Analytical validation of a multi-biomarker algorithmic test for prediction of progressive kidney function decline in patients with early-stage kidney disease. *Clin Proteomics*. Nov 17 2021;18(1):26. doi:10.1186/s12014-021-09332-y
[Analytical validation of a multi-biomarker algorithmic test for prediction of progressive kidney function decline in patients with early-stage kidney disease - PubMed \(nih.gov\)](https://doi.org/10.1186/s12014-021-09332-y)
7. Chan L, Nadkarni GN, Fleming F, et al. Derivation and validation of a machine learning risk score using biomarker and electronic patient data to predict progression of diabetic kidney disease. *Diabetologia*. Jul 2021;64(7):1504-1515. doi:10.1007/s00125-021-05444-0
[Derivation and validation of a machine learning risk score using biomarker and electronic patient data to predict progression of diabetic kidney disease - PubMed \(nih.gov\)](https://doi.org/10.1007/s00125-021-05444-0)
8. Datar M, Ramakrishnan S, Montgomery E, Coca SG, Vassalotti JA, Goss T. A qualitative study documenting unmet needs in the management of diabetic kidney disease (DKD) in the primary care setting. *BMC Public Health*. May 17 2021;21(1):930. doi:10.1186/s12889-021-10959-7
[A qualitative study documenting unmet needs in the management of diabetic kidney disease \(DKD\) in the primary care setting - PubMed \(nih.gov\)](https://doi.org/10.1186/s12889-021-10959-7)